Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease Authors: Ashley En Yi Chong, Andrew Octavian Sasmita, Rhun Yian Koh, Anna Pick Kiong Ling Published: 2026 ABSTRACT AbstractNeurodegenerative diseases (NDDs) including Parkinson's disease (PD) and Alzheimer's disease (AD), are progressive disorders characterised by shared pathological features, including mitochondrial dysfunction, oxidative stress, apoptosis, neuroinflammation, neurotoxic protein buildup, and impaired protein clearance. Current treatments can only relieve disease symptoms but cannot delay the disease progression. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid traditionally used in hepatology, has recently gained attention for its neuroprotective properties. This review critically evaluates UDCA's mechanisms of action, including the restoration of mitochondrial function, inhibition of apoptosis, reduction of oxidative stress and neuroinflammation, and enhancement of autophagy in both PD and AD models. In vitro and in vivo studies demonstrate UDCA's ability to preserve neuronal integrity, improve motor and cognitive outcomes, and reduce toxic protein aggregates. Although early‐phase clinical trials, such as the UDCA for Parkinson's (UP) study in PD, show promising mitochondrial benefits and safety, clinical evidence in AD remains limited. Future directions emphasise the need for large‐scale trials, personalised medicine, improved central nervous system (CNS) delivery strategies, or dietary interventions to modulate UDCA production from the gut microbiome. While not a first‐line treatment, UDCA represents a compelling mitochondrial stabiliser with disease‐modifying potential in NDDs.Keywords: Alzheimer's disease, mitochondrial dysfunction, neurodegenerative diseases, neuroprotection, Parkinson's disease, ursodeoxycholic acid INTRODUCTION Overview of neurodegenerative diseases Neurodegenerative diseases (NDDs) refer to different classes of disorders caused by the progressive degeneration and death of neurons, mainly due to ageing, oxidative stress, toxic protein aggregates and impaired proteostasis. 1 Some examples of NDDs include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, and amyotrophic lateral sclerosis (ALS). Although their clinical symptoms may vary, patients with NDDs often exhibit overlapping cognitive, motor, and behavioural symptoms. For example, cognitive decline predominantly seen in AD may include memory loss, executive dysfunction and disorientation, while motor impairment manifests as tremors, rigidity, bradykinesia, muscle weakness and atrophy in PD, Huntington's, and ALS patients. 2 , 3 , 4 , 5 Behavioural and psychological disturbances, such as depression and apathy, are also prevalent. 3 Furthermore, most NDDs share overlapping pathogenic features, which include protein misfolding and aggregation, mitochondrial dysfunction, oxidative stress, neuroinflammation, as well as impaired clearance of cellular debris, among others. 6 , 7 , 8 , 9 , 10 It is crucial to understand these hallmarks as they provide insights into the nature and progression of the disease and offer potential targets for therapeutic intervention. Table 1 summarises the common hallmarks of NDDs, their mechanisms and the diseases. Table 1Common hallmarks of NDDs, their associated pathological features and diseases.HallmarkDescriptionExamples of NDDsReferencesProtein misfolding and aggregationAbnormal accumulation of misfolded proteins leading to toxic aggregatesAD (Aβ plagues, tau tangles), PD (α‐synuclein Lewy bodies), Huntington's (mHTT), ALS (FUS, TDP‐43 aggregates)[11, 12, 13, 14, 15]Mitochondrial dysfunctionImpaired ATP production, increased ROS, and altered mitochondrial dynamicsAD, PD, ALS[6]NeuroinflammationMicroglial activation leads to the release of pro‐inflammatory cytokinesAD, PD, ALS[7, 16]Oxidative stressExcessive ROS damages lipids, proteins, and DNAAD, PD, ALS[8, 17, 18]Impaired protein clearanceDysfunction of autophagosome‐lysosome fusion or ubiquitin‐proteasome systemsAD, PD, Huntington's[9, 10, 16]Synaptic dysfunctionImpaired synaptic signalling, plasticity, and neurotransmitter releaseAD, PD, Huntington's[19, 20]ExcitotoxicityNeuronal death from overstimulation of glutamate receptorsPD, AD, ALS, Huntington's[21, 22]ApoptosisActivation of intrinsic or extrinsic apoptotic pathways leading to neuronal lossAll major neurodegenerative diseases[23, 24]Abbreviations: AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; Aβ, Amyloid‐beta; FUS, Fused in sarcoma; mHTT, mutant Huntingtin; NDDs, Neurodegenerative diseases; PD, Parkinson's disease; ROS, Reactive oxygen species; TDP‐43, TAR DNA‐bingding protein 43. Common hallmarks of NDDs, their associated pathological features and diseases. Abbreviations: AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; Aβ, Amyloid‐beta; FUS, Fused in sarcoma; mHTT, mutant Huntingtin; NDDs, Neurodegenerative diseases; PD, Parkinson's disease; ROS, Reactive oxygen species; TDP‐43, TAR DNA‐bingding protein 43. Among the various NDDs, AD and PD are the most prevalent, which will be discussed in this review. According to the World Health Organisation (WHO), approximately 57 million people worldwide were living with AD in 2021, while 8.5 million were affected by PD in 2019. 25 , 26 A study conducted by Su et al. 27 forecasted that PD would grow up to 25.2 million cases globally by 2050, highlighting a 112% increase from 2021, which highlights the need for both effective preventive strategies and novel therapeutic interventions for AD and PD. Parkinson's disease PD is a progressive NDD that is typically characterised by motor dysfunction. Although the exact cause of PD is unknown, it is thought to be a combination of environmental, genetic and ageing factors. 28 Genetic mutations in genes such as Leucine‐rich repeat kinase 2 (LRRK2), vacuolar protein sorting 35 (VPS35), and α‐synuclein (SNCA) have been reported to cause PD, while environmental risk factors include chronic exposure to pesticides, heavy metals, post‐encephalitic infection and dietary exposure. 29 Motor symptoms associated with PD include resting tremor, bradykinesia, muscular rigidity, and postural instability. 30 , 31 , 32 PD is also associated with non‐motor symptoms which include sleep disturbances, cognitive decline, depression, anxiety and autonomic dysfunction. 33 Notably, gastrointestinal dysfunction has been copiously reported in patients with PD, and some studies have reported that α‐syn produced in the gut may travel to the brain (body‐first PD theory), acting as initial seeds for brain α‐syn accumulation. 34 , 35 In the CNS, these clinical symptoms arise from the depletion of dopamine activity in the nigrostriatal circuits due to the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), which then inhibits the basal ganglia. 36 , 37 Like other NDDs, the accumulation of Lewy bodies, particularly α‐syn in PD, can also contribute to neuronal toxicity and the spread of pathology throughout the nervous system. 38 Moreover, increased iron levels in subcortical nuclei are also a hallmark of PD. 39 Alzheimer's disease AD is the most common form of dementia, has emerged as a major cause of medical, social, and economic challenges. 40 While the exact cause of AD is unspecified, the aetiology of AD is complex and multifactorial, which involves a combination of genetic, environmental, age and lifestyle factors that contribute to disease onset and progression. One of the major genetic AD risk factors is the APOE‐ε4 allele, which promotes β‐amyloid (Aβ) deposition and impairs its clearance due to disrupted cerebral circulation. 41 Additionally, the extracellular accumulation of Aβ plaques due to imbalanced production and clearance of Aβ peptides, as well as the intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, will also trigger synaptic dysfunction, chronic neuroinflammation, and neuronal loss, particularly in the hippocampus and neocortex. 3 , 42 , 43 , 44 Dysfunction of cholinergic transmission, monoamine oxidase B (MAO‐B) and beta‐site amyloid precursor protein cleaving enzyme 1 (BACE1) overexpression, reactive oxygen species (ROS) production, N‐methyl‐d‐aspartate receptor (NMDAR) overactivity, and dysregulation of metal homeostasis are also known to be the pathogenesis of AD. 45 Metabolic syndromes, such as obesity, hypertension, and diabetes, also contribute to AD by inducing neuroinflammation. 46 Although symptoms may vary, individuals with AD initially show symptoms like episodic memory deficits, cognitive impairments, motor, and language disorders. 47 , 48 As the disease progresses, patients will also experience behavioural and psychological symptoms of dementia (BPSD) symptoms such as aggression, delusions, hallucinations, anxiety, depression, and apathy, which is the main reason for loss of independence and institutionalisation. 49 Similarly to PD, emerging studies have reported various extents of gastrointestinal dysfunction and gut microbiome changes in AD, even at early stages of the disease. 50 , 51 , 52 Dietary interventions such as adherence to the Mediterranean diet may aid in the restoration of the altered gut microbial composition and gut‐derived metabolites in AD, with positive implications for cognitive symptoms. 53 , 54 Current therapeutic strategies and their limitations Even with decades of research, there are still no effective treatments for NDDs. Current strategies focus primarily on symptom management rather than disease modification. For PD, Levodopa is not the most effective medication. 55 Other agents include dopamine agonists, monoamine oxidase‐B (MAO‐B) inhibitors, catechol‐O‐methyltransferase (COMT) inhibitors, and deep brain stimulation. 56 , 57 , 58 Although these medications improve motor function, their long‐term use is associated with complications such as motor fluctuations, dyskinesia, and diminished efficacy over time. 59 Table 2 summarises the available pharmacological treatments for PD, their mechanisms of action, therapeutic purposes, and key limitations. Table 2Current treatments for Parkinson's disease (PD): Mechanisms, purposes, and limitations.TreatmentPurposeLimitationReferencesLevodopa, CarbidopaSlow down the progression by replenishing neuronal levelsLong‐term use associated with chorea and dystonia, diminished efficacy[55, 56, 60, 61]Dopamine agonists (Pramipexole, Ropinirole)Mimic dopamine effects, initial therapy for PDImpulse control disorders, motor complications, long‐term tolerance issues[56, 61]MAO‐B inhibitors (Selegiline, Rasagiline)Prevents dopamine metabolism, relieves motor symptomsLimited efficacy as monotherapy, gastrointestinal side effects[56, 62]COMT inhibitors (Entacapone, Tolcapone, Opicapone)Prevents dopamine metabolism, preserves endogenous dopamine level, reduces motor symptomsDyskinesia, gastrointestinal side effects[56]Deep brain stimulation (DBS)Surgical implantation of a neurostimulator to reduce motor symptomsInvasive, expensive, not suitable for all patients[58]Abbreviations: COMT, Catechol‐O‐Methyltransferase; MAO‐B, Monoamine Oxidase B. Current treatments for Parkinson's disease (PD): Mechanisms, purposes, and limitations. Abbreviations: COMT, Catechol‐O‐Methyltransferase; MAO‐B, Monoamine Oxidase B. For AD, most drugs are designed to alleviate disease symptoms but have little to no effect on disease progression. Current approved therapies include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which enhance cholinergic transmission, as well as memantine, an N‐methyl‐d‐aspartate (NMDA) receptor antagonist that modulates glutamatergic signalling. 63 , 64 Recently, anti‐amyloid monoclonal antibody (Anti‐Aβ mAbs) therapies, such as aducanumab and lecanemab, have also been introduced for the treatment of early‐stage AD by targeting Aβ plaques. 65 Although promising, monoclonal antibody treatments are associated with a high prevalence of side effects, which include oedema and microhaemorrhages, collectively termed amyloid‐related imaging abnormalities (ARIAs). 65 , 66 , 67 , 68 Of note, Aβ plaques have been shown to accumulate decades prior to the onset of symptoms and plaque formation requires a threshold concentration of Aβ for plaque deposition. 69 , 70 , 71 Thus, future strategies should also include efforts to prevent the major aggregation of this primary hallmark of AD by either administering treatments much earlier and for longer periods at lower dosages or by implementing lifestyle changes that are known to reduce the risk for AD. 72 , 73 The available treatments for AD, their mechanism of action, purposes and their limitations are summarised in Table 3. Table 3Current treatments for Alzheimer's disease: Mechanisms, purposes, and limitations.DrugPurposeLimitationReferencesCholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine)Boost acetylcholine levels to improve cognitive functionsProvides only temporary symptomatic relief without halting disease progression[63]NMDA Antagonist (Memantine)Blocks glutamate excitotoxicity to slow cognitive declineLimited efficacy, gastrointestinal side effects[64]Anti‐Aβ mAbs (Aducanumab, Lecanemab)Bind to Aβ to remove amyloid proteins from the brain, improving cognitive functionHigh cost and risk of amyloid‐related imaging abnormalities (ARIAs)[65, 66, 67, 68]Abbreviations: Aβ, Amyloid‐beta; NMDA, N‐Methyl‐d‐Aspartate. Current treatments for Alzheimer's disease: Mechanisms, purposes, and limitations. Abbreviations: Aβ, Amyloid‐beta; NMDA, N‐Methyl‐d‐Aspartate. As illustrated in Tables 2 and 3, existing therapies for PD and AD predominantly relieve the symptoms, and they cannot stop the disease progression. These limitations showed the urgent need for neuroprotective agents that can prevent or slow disease progression. This gap in effective treatment options has led researchers to explore alternative approaches, like repurposing agents such as ursodeoxycholic acid (UDCA) for its neuroprotective effects. This review evaluates the neuroprotective effects of UDCA in PD and AD by synthesizing findings from preclinical and clinical studies, aiming to elucidate its potential as a disease‐modifying agent. SHARED PATHOGENIC MECHANISMS IN PD AND AD: FOCUS ON OXIDATIVE DAMAGE Although different brain regions are affected in PD and AD, resulting in distinct clinical presentations, both diseases share some similar pathogenic mechanisms, which are reviewed in the following subsections. These mechanisms are not only interconnected but also tend to amplify one another, forming a vicious cycle that accelerates neurodegeneration. 74 These shared mechanisms allow the use of therapeutic agents like UDCA, which can target multiple pathological pathways in both AD and PD. Protein aggregation Protein aggregation is a key pathological feature shared by both PD and AD. The pathological hallmark of PD is the formation of Lewy bodies, which are intracellular protein aggregates composed of misfolded, phosphorylated, and polyubiquitinated α‐syn, which can contribute to neuronal dysfunction and degeneration in affected brain regions. 75 In AD, the accumulation of extracellular Aβ plaques and intraneuronal neurofibrillary tangles of hyperphosphorylated tau protein represents the histopathological features that have been associated with disrupted neuronal communication and neuronal death, respectively. 12 The overproduction and misfolding of Aβ peptides initiate plaque formation, which potentiates the phosphorylation of tau, both of which trigger downstream events such as inflammation, trans‐synaptic propagation, and synaptic injury, resulting in cognitive impairment and widespread neuronal loss. 76 , 77 , 78 Neuroinflammation Neuroinflammation is also one of the hallmarks that contributes to the progression of both AD and PD, caused by the reactivity of microglia and astrocytes, which release pro‐inflammatory cytokines such as IL‐1β, IL‐6, and TNF‐α. 74 , 79 These inflammatory mediators exacerbate oxidative stress, neuronal damage, and synaptic loss, creating a toxic neural microenvironment. Reactive microglia are intricately involved in Aβ plaque deposition, intercellular spreading of phosphorylated tau and α‐syn, as well as proteinaceous aggregate degradation. 80 , 81 , 82 Furthermore, reactive microglia also generate ROS and nitric oxide (NO) that damage neurons and accelerate neurodegeneration. 7 , 83 ROS production in microglia is predominantly carried out via NADPH oxidase (NOX), wherein microglia express NOX2 and NOX4. 84 In AD, overexpression and aggregation of tau proteins can trigger neuronal loss and activate the nuclear factor‐κB (NF‐κB) signalling pathway, promoting the spread of tau and further leading to neuroinflammation. 77 In PD, misfolded α‐syn can trigger microglial reactivity, which leads to neuroinflammation and neurodegeneration. 85 Neuroinflammatory‐related ROS production also disrupts BBB function, permitting the entry of peripheral immune cells that further produce more ROS, creating a vicious cycle of worsening brain oxidative stress and redox imbalance. 86 Impaired autophagy and mitophagy Impairment of autophagy and mitophagy also promotes neurodegeneration in PD and AD. Autophagy is essential for clearing damaged proteins and organelles, while mitophagy specifically targets the dysfunctional mitochondria for degradation. 87 The disruption of lysosomal dynamics and proteolytic activity impairs autophagic flux, which leads to the buildup of cellular waste and mitochondrial damage. 9 In PD, mutations in genes like PINK1, PRKN, and LRRK2 will disrupt the PINK1‐Parkin mitophagy pathway, which leads to the accumulation of damaged mitochondria, and can trigger apoptosis and neuronal death. 88 , 89 In AD, accumulation of APP C‐terminal fragments (APP‐CTFs) and the presence of APOE4 impair mitophagy and lysosomal clearance, leading to the buildup of structurally damaged mitochondria, which provokes oxidative stress, synaptic dysfunction, neuronal loss, and ultimately cognitive decline. 90 Mitochondrial dysfunction Mitochondrial impairment is another hallmark of both PD and AD, which contributes to energy failure, increased oxidative stress, loss of neurons, and activation of cell death pathways. 91 In PD, defects in mitochondrial complex I and co‐enzyme Q10 (CoQ10) have been shown to disrupt the electron transport chain (ETC), and mutations in mitochondrial function‐related genes like PINK1, ATP13A2, and PRKN impair mitochondrial quality control, such as mitophagy, mitochondrial dynamics, and stress‐response pathways that normally remove or repair damaged mitochondria to preserve ATP production and limit ROS. 91 , 92 Impaired mitochondrial function reduces ATP synthesis, increases oxidative stress, and damages intracellular components, which leads to dopaminergic neuronal death. 29 , 93 In AD, mitochondrial dysfunction is considered a central contributor to disease progression, leading to impaired ATP production, elevated oxidative stress, disrupted cholesterol homeostasis within mitochondria, neuronal cell death, and cognitive decline. 94 Furthermore, extracellular tau aggregates can exacerbate mitochondrial damage by disrupting mitochondrial morphology in astrocytes and triggering microglia‐mediated phagocytosis of live neurons, eventually promoting neurodegeneration. 77 Several pathological phosphorylation patterns of tau have also been noted to induce varying susceptibilities of neuronal mitochondria to stressors, 95 indicating that mitochondrial changes could be overlooked even in early stages of AD and other tauopathies when proteinaceous aggregates are minimal. Prolonged mitochondrial stress could then lead to faster tau aggregation kinetics, the release of ROS, and further oxidative damage, 96 all of which would negatively impact neural health. Oxidative stress, ROS accumulation, and consequences Oxidative stress caused by the imbalance between radicals and antioxidant defence can lead to excess ROS production, which is a common pathogenic feature in both AD and PD. 97 The importance of considering oxidative stress as a pivotal process in neurodegeneration is highlighted by the fact that hypoxia, which is known to disrupt the cellular redox balance, 98 , 99 , 100 increases BACE1 activity and promotes Aβ plaque deposition in an AD model. 101 Marutani and colleagues, however, recently reported that α‐syn aggregation in the brain of PD mice induces hyperoxia, and a hypoxic treatment regimen prevented aggregate‐induced hyperoxia as well as the death of dopaminergic neurons in the SNpc. 102 In fact, the brain is more susceptible to oxidative stress due to the high levels of peroxidizable lipids and low antioxidant activity, despite utilising 20% of the oxygen taken up by the body. 103 Elevated ROS levels damage DNA, proteins, lipids and carbohydrates, which results in impaired cellular functions and increased susceptibility to neurodegeneration. 104 , 105 Lipid and protein peroxidation can be detected in the plasma of both patients with mild cognitive impairment (MCI) and AD, 106 further warranting future investigation into redox impairments in the context of neurodegeneration. In PD, dysfunctional mitochondria contribute to excessive ROS generation through complex I of the electron transport chain, leading to oxidative damage, microtubule depolymerisation, and degradation of dopaminergic neurons in the substantia nigra. 88 , 107 In AD, oxidative damage is mediated by the excessive production of ROS in the brain, the buildup of Aβ plaques, tau hyperphosphorylation, and synaptic dysfunction, which form a self‐exacerbating loop. 12 Dystrophic neurites in proximity to Aβ plaques have been shown to exhibit the highest level of oxidative stress. 108 Hydrogen peroxide is one of the ROS involved in the oxidative stress cascade of PD and AD. 75 Additionally, metal ions such as iron and copper can catalyse ROS formation, which further contribute to oxidative injury and neurotoxicity in both AD and PD through interactions with Aβ and α‐syn. 105 An overabundance of ROS in the brain also promotes apoptosis, or programmed cell death, driving the progressive neuronal loss in both PD and AD. Stress signals like oxidative stress due to excess ROS, or misfolded proteins such as Aβ and tau aggregates in AD, and α‐syn in PD, will activate pro‐apoptotic members (Bax) or inhibit anti‐apoptotic gene (Bcl‐2). 83 , 109 , 110 Then, the intrinsic pathway of apoptosis, also known as the mitochondrial pathway, is activated through the release of cytochrome c from increased mitochondrial membrane permeability, and caspase‐dependent apoptotic pathways, particularly caspase‐9 and caspase‐3, are activated and trigger the apoptosis of dopaminergic neurons in the substantia nigra. 107 , 111 , 112 Similarly, in AD, excess ROS destabilise the mitochondrial membrane, which also promotes cytochrome c release and activation of caspase cascades, which in turn accelerate synaptic loss, neuronal death, and cognitive decline. 90 , 113 These processes ultimately contribute to the irreversible loss of neurons. URSODEOXYCHOLIC ACID (UDCA) Origin and clinical use Ursodeoxycholic acid (UDCA) is a naturally occurring hydrophilic bile acid that was originally isolated from bear bile in traditional Chinese medicine. 114 It is a secondary bile acid in humans and has been commonly used in the treatment of various liver disorders like primary biliary cholangitis (PBC) and intrahepatic cholestasis. 115 It is the only bile‐acid‐based drug that is FDA‐approved for the management of non‐surgical treatment of cholesterol gallstones by reducing cholesterol and cholesteryl ester concentration in the bile, which improves the gradual dissolution of cholesterol in gallstones. 116 Beyond its hepatoprotective effects, UDCA also exhibits a range of biological activities, such as antioxidant, antiapoptotic, anti‐inflammatory and antitumour properties. 117 In humans, UDCA production is also linked to the gut microbiome, 118 with certain bacterial species such as Lactobacillus reuteri having been shown to metabolize bile acids to yield UDCA. 119 Other endogenous pathways that lead to the formation of UDCA include the epimerization of the 7α‐hydroxy of CDCA by 7α‐ hydroxysteroid dehydrogenase (HSDH) and 7β‐HSDH seen in Clostridium absonum. 120 Interestingly, UDCA concentration has been reported to be reduced in animal models of neurological conditions such as stroke and administration of UDCA was shown to alleviate cognitive decline, 121 Recently, research has explored UDCA's potential as a neuroprotective agent in NDDs like AD and PD, due to its ability to cross the blood‐brain barrier (BBB) and mitigate mitochondrial dysfunction. 122 Chemical structure, pharmacokinetics and safety UDCA, also known as 3α,7β‐dihydroxy‐5β‐cholan‐24‐oic acid, is characterised by a 24‐carbon steroid nucleus consisting of three cyclohexane rings (A, B, C) and one cyclopentane ring (D) in a cis (5β) fusion. 123 , 124 Figure 1 illustrates the chemical structure of UDCA. Chemical structure of Ursodeoxycholic acid (UDCA). 123 This figure was created with ChemDraw. UDCA is a secondary bile acid derived from the 7b‐epimerization of primary bile acid chenodeoxycholic acid (CDCA) by intestinal bacteria such as Ruminococcus gnavus, 123 , 125 , 126 which can in turn modulate gut microbiome composition. 127 Although it is the most hydrophobic bile acids in the human bile pool, UDCA exhibits amphipathic properties due to its unique structure, which contains a hydrophilic component that dissolves in water and a hydrophobic component that dissolves in lipids, so it can interact with different types of membranes, especially in mitochondrial and endoplasmic reticulum (ER) membranes. 128 The hydrophilic nature of UDCA and its conjugated derivatives enhance their ability to cross the BBB, which allows them to exert their effects in the CNS. 129 , 130 , 131 , 132 While UDCA itself has been the focus of most studies and in this review, its taurine‐conjugated derivative, Tauroursodeoxycholic acid (TUDCA) has also been studied extensively in neurodegeneration research. 133 Following oral administration, UDCA is absorbed primarily in the jejunum and ileum through passive diffusion and active transport mediated by bile acid transporters. 134 UDCA undergoes efficient enterohepatic circulation that reabsorbs 95% of the bile acids in the terminal ileum and returns them to the liver via the portal vein, while the remaining bile acids enter the large intestine and are modified by bacteria in the colon before excretion. 135 UDCA has an excellent safety profile due to its hydrophilic nature and non‐toxic characteristics, which enable it to replace and competitively avoid the absorption of harmful bile acids in the ileum, thereby protecting hepatocytes. 114 The standard clinical dose of UDCA for PBC is approximately 13–15 mg/kg/day, divided into two or three doses. 136 In studies exploring neurological applications, similar or slightly adjusted doses have been used depending on species and administration route. Although UDCA is generally safe to use, patients may experience adverse effects such as diarrhoea and abdominal discomfort at higher doses, and the excessive administration of UDCA may also lead to adverse cytotoxicity and hepatobiliary toxicity. 137 , 138 However, there are no significant neurotoxicity or CNS‐related side effects observed in neurodegeneration studies, which supports the potential of repurposing UDCA for long‐term use in chronic NDDs, but further validation in clinical trials is still required. REPORTED PRECLINICAL AND CLINICAL USES OF UDCA IN PD The concentration of primary and secondary bile acids has been shown to be lower in patients with PD. 139 Furthermore, preclinical and clinical studies have begun to highlight how UDCA acts at the cellular and organism levels to modify disease processes in PD, which are further reviewed below and summarized in Table 4 at the end of the section. Table 4Summary of UDCA studies in the context of Parkinson's disease.Study modelEffects of UDCAReferences In vitro studies Sodium nitroprusside‐induced neurotoxic SH‐SY5Y cells Reduction in caspase 3/7 and 9 activitiesUpregulation of the apoptotic suppressor Bcl‐2Downregulation of total ROS, NO, and peroxynitrite productionRescued intracellular glutathione and mitochondrial membrane potential. [109]MPP+ ‐treated SH‐SY5Y cells ROS scavenging propertiesIncreased total mitochondrial content, mitochondrial activity, and ATP production [140]Fibroblasts from LRRK2G2019S‐non‐manifesting PD carriers Rescue of ATP impairment seen in control of LRRK2G2019S‐non‐manifesting patient cells [141]MPP + ‐treated Neuro‐2a cells Decreased LC3‐II/LC3‐I ratio, AMPK expression, and increased p62 expression, indicating a reduction in autophagyAttenuation of ROS accumulationPrevention of MPP+ ‐mediated mitochondrial damage [111] In vivo studies MPTP‐treated mice Shortened climbing time in the pole testLonger time to slip or fall in the rotarod testImproved dopaminergic neuronal survival in the substantia nigraIncreased integrated optical density of dopaminergic projections in the striatum [111]MPTP‐treated mice treated with UDCA‐containing nanovesicles Significant improvement in suspension and pole climbing testsIncreases tyrosine hydroxylase expression in striatal neuronsDownregulated JAK/STAT pathway, suggesting lowered neuroinflammationUpregulation of mitochondrial repair and dopamine metabolism genes [140]Rotenone‐treated male Wistar rats Rescue of locomotor, rearing, and ambulation deficitsIncreased striatal ATP concentration and a rescue of striatal dopamine levelsReduced neuroinflammation and apoptosis [142]LRRK2G2019S transgenic flies Doubling of photoreceptor responseTripling of the lamina and medulla neuronal responses [141] Clinical study UP study: Early‐stage patients with PD (19 men, 12 women) High tolerability (97.6%) after 48 weeks of treatment followed by an 8‐week washout phaseIncreased ATP hydrolysis and inorganic phosphate levels indicative of improved mitochondrial functionModest improvements in cadence and stride variability [143, 144]Abbreviations: AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; AMPK, AMP‐activated protein kinase; APOE, Apolipoprotein E; ARIAs, Amyloid‐Related Imaging Abnormalities; ATP, Adenosine triphosphate; Aβ, Amyloid‐beta; Bax, Bcl‐2‐associated X protein; Bcl‐2, B‐cell lymphoma 2; COMT, Catechol‐O‐Methyltransferase; JAK/STAT, Janus kinase/Signal transducer and activator of transcription; LC3, Microtubule‐associated protein 1 A/1B‐light chain 3; LRRK2, Leucine‐rich repeat kinase 2; MAO‐B, Monoamine oxidase B; MMP, Mitochondrial membrane potential; MPTP, 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine; NO, Nitric oxide; PD, Parkinson's disease; p62, Sequestosome‐1; ROS, Reactive oxygen species; SH‐SY5Y, Human neuroblastoma cell line; TUDCA, Tauroursodeoxycholic acid; UDCA, Ursodeoxycholic acid; UP, UDCA for Parkinson's (study); α‐syn, alpha‐synuclein. Summary of UDCA studies in the context of Parkinson's disease. Reduction in caspase 3/7 and 9 activitiesUpregulation of the apoptotic suppressor Bcl‐2Downregulation of total ROS, NO, and peroxynitrite productionRescued intracellular glutathione and mitochondrial membrane potential. Reduction in caspase 3/7 and 9 activities Reduction in caspase 3/7 and 9 activities Upregulation of the apoptotic suppressor Bcl‐2 Upregulation of the apoptotic suppressor Bcl‐2 Downregulation of total ROS, NO, and peroxynitrite production Downregulation of total ROS, NO, and peroxynitrite production Rescued intracellular glutathione and mitochondrial membrane potential. Rescued intracellular glutathione and mitochondrial membrane potential. ROS scavenging propertiesIncreased total mitochondrial content, mitochondrial activity, and ATP production ROS scavenging properties ROS scavenging properties Increased total mitochondrial content, mitochondrial activity, and ATP production Increased total mitochondrial content, mitochondrial activity, and ATP production Rescue of ATP impairment seen in control of LRRK2G2019S‐non‐manifesting patient cells Rescue of ATP impairment seen in control of LRRK2G2019S‐non‐manifesting patient cells Rescue of ATP impairment seen in control of LRRK2G2019S‐non‐manifesting patient cells Decreased LC3‐II/LC3‐I ratio, AMPK expression, and increased p62 expression, indicating a reduction in autophagyAttenuation of ROS accumulationPrevention of MPP+ ‐mediated mitochondrial damage Decreased LC3‐II/LC3‐I ratio, AMPK expression, and increased p62 expression, indicating a reduction in autophagy Decreased LC3‐II/LC3‐I ratio, AMPK expression, and increased p62 expression, indicating a reduction in autophagy Attenuation of ROS accumulation Attenuation of ROS accumulation Prevention of MPP+ ‐mediated mitochondrial damage Prevention of MPP+ ‐mediated mitochondrial damage Shortened climbing time in the pole testLonger time to slip or fall in the rotarod testImproved dopaminergic neuronal survival in the substantia nigraIncreased integrated optical density of dopaminergic projections in the striatum Shortened climbing time in the pole test Shortened climbing time in the pole test Longer time to slip or fall in the rotarod test Longer time to slip or fall in the rotarod test Improved dopaminergic neuronal survival in the substantia nigra Improved dopaminergic neuronal survival in the substantia nigra Increased integrated optical density of dopaminergic projections in the striatum Increased integrated optical density of dopaminergic projections in the striatum Significant improvement in suspension and pole climbing testsIncreases tyrosine hydroxylase expression in striatal neuronsDownregulated JAK/STAT pathway, suggesting lowered neuroinflammationUpregulation of mitochondrial repair and dopamine metabolism genes Significant improvement in suspension and pole climbing tests Significant improvement in suspension and pole climbing tests Increases tyrosine hydroxylase expression in striatal neurons Increases tyrosine hydroxylase expression in striatal neurons Downregulated JAK/STAT pathway, suggesting lowered neuroinflammation Downregulated JAK/STAT pathway, suggesting lowered neuroinflammation Upregulation of mitochondrial repair and dopamine metabolism genes Upregulation of mitochondrial repair and dopamine metabolism genes Rescue of locomotor, rearing, and ambulation deficitsIncreased striatal ATP concentration and a rescue of striatal dopamine levelsReduced neuroinflammation and apoptosis Rescue of locomotor, rearing, and ambulation deficits Rescue of locomotor, rearing, and ambulation deficits Increased striatal ATP concentration and a rescue of striatal dopamine levels Increased striatal ATP concentration and a rescue of striatal dopamine levels Reduced neuroinflammation and apoptosis Reduced neuroinflammation and apoptosis Doubling of photoreceptor responseTripling of the lamina and medulla neuronal responses Doubling of photoreceptor response Doubling of photoreceptor response Tripling of the lamina and medulla neuronal responses Tripling of the lamina and medulla neuronal responses High tolerability (97.6%) after 48 weeks of treatment followed by an 8‐week washout phaseIncreased ATP hydrolysis and inorganic phosphate levels indicative of improved mitochondrial functionModest improvements in cadence and stride variability High tolerability (97.6%) after 48 weeks of treatment followed by an 8‐week washout phase High tolerability (97.6%) after 48 weeks of treatment followed by an 8‐week washout phase Increased ATP hydrolysis and inorganic phosphate levels indicative of improved mitochondrial function Increased ATP hydrolysis and inorganic phosphate levels indicative of improved mitochondrial function Modest improvements in cadence and stride variability Modest improvements in cadence and stride variability Abbreviations: AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; AMPK, AMP‐activated protein kinase; APOE, Apolipoprotein E; ARIAs, Amyloid‐Related Imaging Abnormalities; ATP, Adenosine triphosphate; Aβ, Amyloid‐beta; Bax, Bcl‐2‐associated X protein; Bcl‐2, B‐cell lymphoma 2; COMT, Catechol‐O‐Methyltransferase; JAK/STAT, Janus kinase/Signal transducer and activator of transcription; LC3, Microtubule‐associated protein 1 A/1B‐light chain 3; LRRK2, Leucine‐rich repeat kinase 2; MAO‐B, Monoamine oxidase B; MMP, Mitochondrial membrane potential; MPTP, 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine; NO, Nitric oxide; PD, Parkinson's disease; p62, Sequestosome‐1; ROS, Reactive oxygen species; SH‐SY5Y, Human neuroblastoma cell line; TUDCA, Tauroursodeoxycholic acid; UDCA, Ursodeoxycholic acid; UP, UDCA for Parkinson's (study); α‐syn, alpha‐synuclein. In vitro Studies In vitro studies using PD cellular models, such as SH‐SY5Y neuroblastoma cells, were used to investigate the protective effects of UDCA against 6‐hydroxydopamine (6‐OHDA)‐induced neurotoxicity. 109 In the study, 50–200 μM UDCA significantly protected SH‐SY5Y cells observed via the enhancement of cell viability. Such improvements were associated with a reduction of caspase 3/7 and caspase 9 activity as well as apoptosis. While sodium nitroprusside induced the expression of Bax, an apoptotic inducer, treatment with UDCA upregulated Bcl2, an apoptotic suppressor, leading to an increased Bcl‐2/Bax ratio which indicates ameliorated apoptosis. UDCA‐treated cells also produced less total ROS, NO, and peroxynitrite, while also alleviating the sodium nitroprusside‐induced reduction in intracellular glutathione concentration, a major protective antioxidant, in a dose‐dependent manner. Functionally, sodium nitroprusside‐mediated mitochondrial membrane potential reduction—which suggests mitochondrial dysfunction—was alleviated by UDCA and suggests improvement in neuronal health and trafficking. 109 A recent study by Zhang et al. reported a nanovesicle‐based approach to deliver UDCA to 1‐methyl‐4‐phenylpyridinium (MPP+)‐treated SH‐SY5Y cells, an In vitro model of oxidative stress. UDCA‐containing nanovesicles derived from macrophages were uptaken and tolerated by the SH‐SY5Y cells. UDCA delivery induced ROS scavenging in the MPP+SH‐SY5Y cells and significantly rescued ATP level decline to baseline non‐MPP+ ‐treated cells at a dosage of 31.25 µM. 140 These rescue effects were correlated with an increase in both total mitochondrial content and mitochondrial activity, leading to an elevated ATP production. MPP+ also induced morphological changes of SH‐SY5Y cells to become more rod‐shaped and UDCA treatment rescued these morphological alterations, presumably due to its antioxidative and neuroprotective nature. Moreover, a study carried out by Mortiboys et al. demonstrated that fibroblasts derived from both manifesting (M‐LRRK2G2019S) and non‐manifesting (NM‐LRRK2G2019S) carriers of the Parkinson's‐linked LRRK2G2019S mutation exhibited reduced mitochondrial function as they showed decreased intracellular ATP levels, impaired basal and maximal oxygen consumption, and reduced coupled respiration. 141 UDCA treatment improved ATP levels and mitochondrial respiration in NM‐LRRK2G2019S fibroblasts, which underscored a rescue effect on mitochondrial function. 141 Lastly, UDCA improved cell viability and protected dopaminergic neurons in Neuro‐2a cells treated with MPP+ by inhibiting ROS accumulation, maintaining mitochondrial membrane potential, and preventing ATP depletion. Additionally, MPP+ increased the ratio of LC3‐II/LC3‐I as well as AMP‐activated protein kinase (AMPK), and decreased p62 expression, indicating elevated autophagic flux. Treatment with UDCA reversed the MPP+ ‐mediated autophagic alterations, suggesting that UDCA may exert protective effects against PD‐associated stressors at the cellular level. 111 The authors noted, however, that although 100−200 μg/mL of UDCA treatment did not reduce cell viability even upon 48 h of treatment, high dosage of UDCA (i.e., 400−800 μg/mL) induced a mild decrease in cell viability. this further highlights that correctly dosing UDCA while also factoring time and bioavailability should be a focus if UDCA is to be developed as a therapeutic or preventative intervention. Taken together, the discussed preclinical studies investigating the beneficial effects of UDCA in the context of PD highlighted the antioxidative nature of the compound with various downstream effects of ameliorated apoptosis, reduced ROS accumulation, and restored mitochondrial functions, all of which are pathological phenotypes exhibited primarily by neurons. In vivo studies In vivo studies further support UDCA's efficacy. For example, in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated mice, a model of PD, UDCA treatment improved motor function (e.g., shorter climbing time in the pole test). 111 Furthermore, dopaminergic neuron survival in the substantia nigra as well as integrated optical density of dopaminergic neurons in the striatum were shown to be improved, presumably by reducing oxidative stress and energy depletion, promoting autophagy, inhibiting apoptosis, and activating pathways like AMPK/mTOR and PINK1/Parkin that are responsible for mitochondrial quality and autophagic regulation which the authors confirmed via in vitro assays discussed in the previous sub‐section. 111 These findings reinforce the therapeutic relevance of UDCA in PD by demonstrating its effects on both pathology and behaviour in animal models. As discussed in the previous in vitro section, the study by Zhang et al. further investigated the effects of UDCA‐containing nanovesicles in the MPTP mouse model of PD. Although the nanovesicles were primarily detected in the liver, the primary site of UDCA metabolism, UDCA nanovesicle administration of 5 mg/kg via the tail vein resulted in the detection of the nanovesicle in the brain as early as 0.5 h, peaking between 4 and 10 h, and was undetectable after 24 h. Treated MPTP mice performed significantly better in the suspension and pole climbing tests. UDCA nanovesicles modified with triphenylphosphonium, an agent that enhances mitochondrial targeting due to its positively charged nature, caused the highest increase in tyrosine hydroxylase expression in striatal neurons. Transcriptomic analysis of the treated mouse striatum revealed downregulated JAK/STAT pathway, suggesting lowered neuroinflammation. Furthermore, upregulation of mitochondrial repair and dopamine metabolism genes, including Th, was reported upon treatment with UDCA. Lastly, histopathological characterisation of other organs—including the liver, kidney, and lungs—revealed no detrimental changes and thus suggests the relative safety of the nanovesicle approach to systemically deliver UDCA. 140 The therapeutic relevance of UDCA in the MPTP mouse models is further supported when compared alongside with other naturally derived neuroprotectants that similarly ameliorate motor deficits, oxidative stress, inflammation, and dopaminergic neurodegeneration. 145 , 146 For example, ursolic acid (UA), a pentacyclic triterpenoid found in herbs and fruits, improved motor performance and preserved dopaminergic neurons in MPTP‐intoxicated mice, as evidenced by enhanced rotarod, hanging and narrow beam walking performance in MPTP‐intoxicated mice, as well as increased tyrosine hydroxylase (TH) expression in the substantia nigra, indicating preservation of dopaminergic cells. 145 Additionally, UA also strengthened antioxidant defences by elevating catalase and glutathione levels while reducing lipid peroxidation and nitrite accumulation, thereby restoring striatal dopamine concentrations. 145 In a complementary study, UA also exhibited strong anti‐inflammatory activity by suppressing microglial activation, inhibiting NF‐κB and MAPK signalling, and decreasing proinflammatory cytokines (TNF‐α, IL‐1β) while upregulating IL‐10, thereby mitigating neuroinflammation in the SNpc of MPTP‐treated mice. 147 Similarly, chlorogenic acid (CGA), a dietary polyphenol abundant in coffee and plant‐based foods, also rescued motor coordination in MPTP mice, as reflected by improved rotarod performance, increased TH expression in the nigrostriatal pathway, and attenuated neuroinflammation by decreasing inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP), and NF‑κB activation and reducing TNF‑α, IL‑1β while elevating IL‑10. 146 Mechanistically, CGA also prevented mitochondrial dysfunction by enhancing the activity of complexes I, IV, and V, increasing mitochondrial glutathione levels, inhibiting Bax and caspase‐3, and promoting Bcl‐2 expression, thereby protecting dopaminergic neurons via the Akt, ERK1/2 and modulation of GSK3β signaling. 148 Together, these findings from UA and CGA reinforce that naturally derived compounds like UDCA can counteract MPTP‑induced neurodegeneration in PD. Another study by Abdelkader et al. showed that in a Wistar rat rotenone model of PD, a 3‐week regimen of UDCA injections at 50 mg/kg rescued locomotor, rearing, and ambulation deficits. The behavioural improvements were associated with a concomitant rescue of dopamine and ATP concentration in the striatum, reduced neuroinflammatory‐associated NF‐κB and TNF expression, as well as suppressed apoptosis via a downregulation of caspases 3, 8, and 9. 142 Lastly, Mortiboys and colleagues showed that transgenic flies with dopaminergic expression of LRRK2G2019S exhibited impaired visual contrast response function due to an approximately 30% reduction in photoreceptor response and a 15% depletion of neuronal populations in the lamina and medulla of the fly optic lobe. 141 By feeding transgenic flies with UDCA, the authors observed a doubling of the photoreceptor response and tripling of the lamina and medulla neuronal responses. Such changes were attributed to the observed in vitro neuroprotective effects of UDCA via amelioration of mitochondrial and energetic deficits. Current and emerging clinical trials The most notable clinical investigation of UDCA to date is the UP study (NCT03840005), which is a phase II, randomised, double‐blind, placebo‐controlled, which investigates the safety, tolerability, and preliminary efficacy of high‐dose UDCA (30 mg/kg/day orally) in individuals with early‐stage PD. 143 , 144 According to the published protocol, the study enrolled 31 participants across two centres: Sheffield Teaching Hospitals (STH) and University College London Hospitals (UCLH). Participants were diagnosed within 3 years of study entry, had a sustained response to dopaminergic therapy, and underwent treatment lasting 48 weeks followed by an 8‐week washout phase. 144 The primary endpoint was safety and tolerability, assessed through adverse event reporting, clinical blood tests, and laboratory monitoring, with high compliance (97.6%) indicating good tolerability. Secondary endpoints included mechanistic measures such as midbrain bioenergetics assessed by 31P‐MRS imaging, showing increased ATP hydrolysis and inorganic phosphate levels indicative of improved mitochondrial function, and sensor‐based objective gait analysis, which suggested modest improvements in cadence and stride variability. Clinical motor progression was evaluated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale, part III (MDS‐UPDRS‐III), but no significant differences were observed between the UDCA and placebo groups in these subjective clinical scores. 143 The result of the trial showed that high‐dose UDCA is safe and well tolerated in early‐stage PD, with only mild and transient gastrointestinal side effects. These findings suggest the potential bioenergetic benefits of UDCA, although larger and longer‐term studies are needed to validate these outcomes. 143 Limitations While UDCA shows some really promising neuroprotective effects of UDCA observed in preclinical and early clinical studies, there are several limitations that restrict the therapeutic translation of UDCA in PD. One major limitation is that the In vitro and In vivo studies rely on toxin‐induced or simplified cellular models that do not fully recapitulate the chronic, progressive, and complex nature of human PD, especially in cases where the causes are unknown. Additionally, the mechanism of UDCA might not address all aspects on PD. Although it might hold promise in rescuing oxidative stress effects and mitochondrial function, UDCA might not directly affect protein aggregates that might be the root cause of the disease. The cellular models In vitro utilised usually lack dopaminergic neuron specificity or mature neuronal characteristics, which further limits the relevance of the observed effects. 109 , 141 Moreover, mechanistic insights into UDCA's mode of action remain incomplete, and its long‐term efficacy and safety have yet to be firmly established. 111 , 141 Existing clinical trials are limited by sample sizes, short treatment durations, and exploratory outcome measures, which makes it difficult to draw definitive conclusions on disease modification. 143 PRECLINICAL EVIDENCE AND CLINICAL POTENTIAL OF BILE ACIDS IN AD: FOCUS ON TUDCA AND UDCA Similarly to PD, patients with AD have been shown to exhibit lower concentrations of primary bile acids in circulation, 149 suggesting that restoration of their levels may have neuroprotective potential. Although preclinical research into the application of UDCA in AD is far smaller in number compared to the PD research, several studies highlighted the compound's potential as an AD therapy and prevention, which is summarized in Table 5 at the end of the section. Table 5Summary of UDCA studies in the context of Alzheimer's disease. Study model In vitro studies Effects of UDCAReferencesSporadic AD and PSEN1 fibroblasts Modest restoration of impaired mitochondrial respiration and MMPIncrease in the mitochondrial fission protein, Drp1, which is also required for UDCA to exert its neuroprotective effects [150]BV2 microglia treated with Aβ42 Suppression of LPS‐ and Aβ‐mediated expression of IL‐1β and NO [151]Abbreviations: AD, Alzheimer's disease; Aβ, Amyloid‐beta; BV2, Murine microglial cell line; Drp1, Dynamin‐related protein 1; IL‐1β, Interleukin‐1 beta; NO, Nitric Oxide; PSEN1, Presenilin 1; UDCA, Ursodeoxycholic acid. Summary of UDCA studies in the context of Alzheimer's disease. Study model In vitro studies Modest restoration of impaired mitochondrial respiration and MMPIncrease in the mitochondrial fission protein, Drp1, which is also required for UDCA to exert its neuroprotective effects Modest restoration of impaired mitochondrial respiration and MMP Modest restoration of impaired mitochondrial respiration and MMP Increase in the mitochondrial fission protein, Drp1, which is also required for UDCA to exert its neuroprotective effects Increase in the mitochondrial fission protein, Drp1, which is also required for UDCA to exert its neuroprotective effects Suppression of LPS‐ and Aβ‐mediated expression of IL‐1β and NO Suppression of LPS‐ and Aβ‐mediated expression of IL‐1β and NO Suppression of LPS‐ and Aβ‐mediated expression of IL‐1β and NO Abbreviations: AD, Alzheimer's disease; Aβ, Amyloid‐beta; BV2, Murine microglial cell line; Drp1, Dynamin‐related protein 1; IL‐1β, Interleukin‐1 beta; NO, Nitric Oxide; PSEN1, Presenilin 1; UDCA, Ursodeoxycholic acid. In vitro studies A study by Bell et al. demonstrated UDCA treatment (100 nM for 24 h) significantly improved mitochondrial function in fibroblasts derived from both sporadic (sAD) and familial AD (fAD) patients. The research team observed that AD fibroblasts exhibited mitochondrial dysfunction, characterised by reduced mitochondrial membrane potential (MMP), impaired respiration, and abnormal morphology, with elongated mitochondria and perinuclear clustering. 150 Treatment with UDCA restored mitochondrial membrane potential by 12%–28% in sporadic AD and 19%–21% in PSEN1 fibroblasts, as well as improving mitochondrial respiration, and corrected fission/fusion imbalances by increasing the expression and mitochondrial localisation of dynamin‐related protein 1 (Drp1), which highlights its role in rescuing bioenergetic deficits and restoring mitochondrial dysfunction in AD. 150 Drp1 knockdown led to the abolishment of the protective effects of UDCA on sporadic AD and PSEN1 fibroblasts, suggesting that UDCA requires a functional mitochondrial structure to exert its effects. 150 Evidence from In vitro studies using BV2 microglial cells shows that UDCA can mitigate Aβ‐induced neuroinflammation through the inhibition of NF‐κB activation, resulting in a significant downregulation of key pro‐inflammatory mediators, such as TNF‐α and NO. 151 Additionally, another study done by Ko et al. reported that UDCA (1 mM) significantly reduced LPS‐induced inflammation in RAW 264.7 macrophages by decreasing NO production and downregulating pro‐inflammatory cytokines, while increasing anti‐inflammatory IL‐10. 152 Although this model did not specifically investigate AD‐related pathology, it focuses only on general inflammatory responses to show that UDCA has anti‐inflammatory properties. 152 In vivo studies To date, there has been no In vivo study that investigates the usage of UDCA to mitigate AD pathology. Instead, most In vivo studies investigating bile acids in AD focused on TUDCA, the taurine‐conjugated form of UDCA, rather than UDCA itself. Approximately 90% of an orally administered UDCA dose is absorbed and transported via the portal vein to the liver, where it is efficiently extracted and conjugated with taurine rather than within the CNS. The resulting TUDCA can then subsequently enter the BBB via systemic circulation to exert its neuroprotective effects. 123 , 153 The robust neuroprotection, amyloid reduction, and cognitive rescue observed in these animal models may be largely due to TUDCA's enhanced bioavailability and better mitochondrial targeting efficacy compared to unconjugated UDCA. 153 , 154 This pharmacokinetic advantage may partly explain why stronger neuroprotective outcomes are consistently reported in TUDCA for AD models. For example, in APP/PS1 mice at 8 months of age, 6 months of dietary TUDCA supplementation reduced hippocampal and cortical Aβ plaque burden by 30%–65% and rescued cognitive deficits in memory tasks due to its modulatory effect on connective tissue growth factor (CGTF) and its anti‐apoptotic properties. 154 Additional studies also reported that TUDCA's mechanisms in AD models include modulation of apoptotic pathways, reduction of oxidative stress, and potential effects on amyloid precursor protein processing. 155 While the findings with TUDCA are promising, they cannot be directly extrapolated to UDCA. Although UDCA and TUDCA share similar core structures and mechanisms, such as mitochondrial stabilisation and NF‐κB pathway inhibition, direct evidence of UDCA's efficacy in AD models remains limited and is an area requiring further investigation. 154 Thus, although UDCA might be a promising therapeutic candidate, the taurine‐conjugated version, TUDCA, might even be better simply because of increased bioavailability. Nevertheless, this does not diminish the therapeutic relevance of UDCA as the difference between TUDCA and UDCA is just the taurine conjugate. Overall, the success of TUDCA in mitigating AD pathology provides a strong rationale for exploring UDCA's potential. Potential for clinical translation The phase 2a PEGASUS trial, which completed in 2020, assessed the effect of sodium phenylbutyrate and TUDCA on a cohort of 95 patients with MCI or early AD over a period of 24 weeks. 156 The combinatorial treatment reduced levels of total tau and p‐tau181 in the cerebrospinal fluid (CSF) while raising the CSF Aβ42/40 ratio, indicating reduced tau load in the brain and Aβ clearance respectively. Interestingly, patients of the PEGASUS trial treated with the combinatorial treatment also showed elevated 8‐OHdG levels which indicates increased oxidative stress, warranting further investigation. Despite the promising results from preclinical studies, no ongoing or planned clinical trials have yet been identified to specifically investigate UDCA for AD in clinicaltrials. gov in the current registries as of January 2025. 157 The 2025 AD pipeline includes 182 trials across 138 drugs, with 74% as disease‐targeted therapies focusing on processes like Aβ‐related pathophysiology (18%), neuroinflammation (17%), and metabolism/bioenergetics (6%), but UDCA remains absent from Phase 1–3 AD trials. 157 There are 46 repurposed drugs that comprise 33% of the 2025 AD drug development pipeline, but there are no AD‐specific entries for small molecules like UDCA. 157 However, its well‐established safety profile from decades of FDA‐approved use in primary biliary cholangitis provides a strong rationale for its potential repurposing. Moreover, the recent UP Study done on PD has also demonstrated the safety of UDCA and its ability to engage mitochondrial targets in patients with PD. 143 Given the shared pathological mechanisms between PD and AD, these findings suggest UDCA can be used as a potential therapeutic against NDDs. From a translational perspective, it is also important to consider metabolic efficiency when comparing UDCA and TUDCA because the taurine conjugation of UDCA occurs primarily in the liver, 123 and patients with AD often present with age‐related metabolic disturbance and systemic comorbidities, 158 which may affect the conversion of UDCA to TUDCA. As the in vivo evidence in AD models currently supports TUDCA as the more bioavailable form of UDCA, direct TUDCA administration may provide more predictable CNS exposure and therapeutic efficacy in clinical settings. Nevertheless, UDCA remains of significant interest due to its established safety profile and mitochondrial‐targeting properties. Research should prioritise establishing UDCA's efficacy in AD animal models, alongside pharmacokinetic comparisons with TUDCA, before progressing to clinical evaluation in AD populations to bridge the current gap between mechanistic promise and clinical translation. Together, these data outline a translational pipeline where UDCA remains at a preclinical to very early clinical stage for AD. Therefore, future research must first establish UDCA's efficacy in AD animal models, and pharmacokinetic comparisons with TUDCA, before progressing to clinical trials in AD populations to validate its therapeutic potential and bridge the current gap between preclinical promise and clinical reality. Limitations Despite the preclinical evidence for neuroprotection in AD via mitochondrial, anti‐apoptotic, and anti‐inflammatory pathways, there are still several limitations in the current understanding of UDCA's effects in AD. Currently, there is no direct In vivo evidence that confirms the efficacy of UDCA against the mechanisms of cognitive decline in AD, as most studies rely on acute models that may not replicate chronic disease progression. Most research focuses on TUDCA due to its better solubility, BBB penetration, and stronger preclinical validation in AD models, while UDCA's lower brain permeability raises concerns about therapeutic effectiveness. 159 Although UDCA is FDA‐approved for liver conditions, no clinical trials have assessed its use in AD, which leaves a gap in understanding its brain uptake and long‐term effects. 117 Additionally, prolonged UDCA use may disrupt bile acid metabolism or gut microbiota, and its anti‐apoptotic effects could potentially interfere with normal cellular turnover in ageing brains. 160 Future research should directly compare UDCA in chronic AD models and conduct Phase I/II trials to evaluate its therapeutic potential. If these studies demonstrate insufficient efficacy or unfavourable pharmacokinetics, UDCA may not be suitable for AD. CONVERGENT MECHANISMS OF ACTION OF UDCA IN ELICITING NEUROPROTECTION AGAINST AD AND PD PATHOLOGIES Upon crossing the BBB, UDCA exerts neuroprotective effects through multiple converging mechanisms, as illustrated in Figure 2. Mechanisms of action of UDCA in neuroprotection in the context of PD and AD. UDCA acts through several pathways: restoration of mitochondrial function upon oxidative stress, inhibiting apoptosis, suppressing neuroinflammation, and enhancing autophagy. Inhibitory effects of UDCA on pathological cellular processes are annotated with blue lines. These actions collectively mitigate neuronal loss in PD and AD. AD, Alzheimer's disease; PD, Parkinson's disease; UDCA, Ursodeoxycholic acid. As discussed in the previous sections, in the context of PD, UDCA enhances mitochondrial function by promoting ATP synthesis and stabilising the mitochondrial membrane potential, thereby reducing mitochondrial fragmentation. 140 , 161 Additionally, UDCA inhibits intrinsic apoptosis by blocking cytochrome c release and reducing caspase‐3/9 activation, which preserves neuronal viability. 162 , 163 It also possesses antioxidant activity through the neutralisation of ROS, upregulation of antioxidant enzymes such as superoxide dismutase (SOD) and catalase to mitigate oxidative stress‐induced neuronal damage. 164 Furthermore, UDCA suppresses neuroinflammatory responses by inhibiting microglial activation and NF‐κB signalling, which decreases proinflammatory cytokine production and shows anti‐inflammatory effects. 165 Finally, UDCA promotes cellular homeostasis by inducing LC3B expression and enhancing lysosomal degradation, which facilitates the clearance of misfolded proteins through autophagy. 166 The neuroprotective effects of UDCA in PD models primarily involve the restoration of mitochondrial function, attenuation of oxidative stress, and regulation of autophagy and apoptosis. UDCA counteracts mitochondrial dysfunction, particularly complex I impairment, by stabilising membrane potential, boosting ATP production, and reducing ROS. 111 , 141 UDCA also modulates autophagy via PINK1/Parkin and AMPK/mTOR pathways, which enhance the clearance of toxic aggregates like α‐syn. 110 , 143 Additionally, UDCA also suppresses apoptosis by inhibiting caspase activation (caspase‐3/7, ‐9), balancing Bcl‐2/Bax ratios, and blocking cytochrome c release. 109 It also mitigates neuroinflammation by reducing NF‐κB and TNF‐α. 142 These mechanisms collectively preserve dopaminergic neurons, improve motor function, and maintain striatal dopamine levels. In AD models, UDCA mainly shows neuroprotective effects through three primary mechanisms. Firstly, it restores mitochondrial function by stabilising membrane potential, improving energy production, and regulating fission/fusion dynamics. 150 UDCA reduces neuroinflammation by suppressing microglial activation, inhibiting pro‐inflammatory cytokines, and modulating the TGR5/AKT/NF‐κB pathway. 165 , 166 Besides, it also decreases oxidative stress and protects against Aβ‐induced neuronal damage. 167 Another study investigated the protective effects of UDCA in stroke model mice and reported that UDCA administration regulated microglial inflammatory response by inhibiting NLRP3‐related inflammatory cytokines via the TGR5/PKA pathway. Although the study by Zhang and colleagues was carried out in the context of stroke, UDCA's anti‐inflammatory effects might aid in curbing excessive neuroinflammation also observed in patients with PD and models. 143 The alleviation of neuroinflammation seen by UDCA administration has also been shown in models of multiple sclerosis, and spinal cord injury, 168 , 169 suggesting that dampening neuroinflammation may exert neuroprotection in the context of other NDDs. These combined actions showed that UDCA can be a promising therapeutic candidate for AD, but further research is needed to optimise its efficacy and brain delivery. In summary, UDCA may exert positive convergent effects to counteract AD and PD pathology primarily through the stabilization of metabolic deficits critical in both NDDs. As metabolic deficits occur early as a driver of NDDs 170 and may lead to persistent oxidative stress, subsequent neuroinflammation, and eventual neurodegeneration, UDCA and TUDCA may act as an upstream inhibitor of the cascade leading to neurodegeneration, which warrants further investigation. FUTURE DIRECTIONS Current research on the potential usage of UDCA as a therapeutic agent against PD and AD has mostly been done with its taurine‐conjugated form, TUDCA. 171 , 172 Given that alterations in bile acid synthesis have been reported in both NDDs discussed in this review, research into bile acids with neuroprotective effects should be further expanded upon. Although the neuroprotective potential of UDCA in PD and AD is supported by preclinical studies and early‐phase clinical research, the results may not translate perfectly to human patients. Future studies should focus on expanding clinical validation, optimising therapeutic strategies, and exploring innovative technologies to improve drug delivery and patient outcomes for advancing UDCA as a disease‐modifying treatment in NNDs. Expanded clinical trials Current trials have mainly focused on early‐stage and acute PD, with limited exploration in AD. Future studies should expand to include more diverse patient populations with diverse disease severity and genetic backgrounds and incorporate longer follow‐up durations to better assess therapeutic outcomes. Besides, authors of the UP study in PD mentioned that larger, phase IIb/III trials with greater power to detect clinical efficacy should be done, and the paper also underscored UDCA's potential as a promising candidate for further investigation. 143 Combination therapy and leveraging the gut‐brain axis Due to the complex nature of NDDs, monotherapy with UDCA alone may be insufficient to achieve optimal therapeutic outcomes. Combining UDCA with existing symptomatic treatments such as levodopa in PD or cholinesterase inhibitors in AD could enhance the therapeutic efficacy by simultaneously targeting disease progression and symptom management. However, the potential synergistic or antagonistic interactions between UDCA and these drugs remain unexplored. No studies have evaluated the pharmacodynamic interactions, long‐term safety, or combined efficacy in preclinical or clinical settings. Future research should prioritise pharmacokinetics and pharmacodynamic studies on UDCA with existing drugs, as well as toxicity and safety studies to determine their optimal dosing regimens to avoid additional adverse effects. By addressing these gaps, researchers can determine whether UDCA‐based combination strategies offer a viable approach for improving outcomes in PD and AD. Notably, an alternative combination strategy bypasses direct brain targeting by focusing on the gut‐microbiome‐brain axis. In a mouse model of non‐alcoholic fatty liver disease, UDCA administration was shown to partially revert changes in the gut microbiome and dampen hepatic inflammation, 173 suggesting that UDCA might exert its effects via bile acid metabolism in the gut microbiome. A study by Mao et al. (2023) demonstrated that combining dioscin, a gut‐modulating steroidal saponin, with UDCA alleviated PD pathology in MPTP‐induced mice by restoring gut microbiota balance, increasing neuroprotective bile acids, and reducing neuroinflammation and oxidative stress without requiring BBB penetration. 174 In fact, a study showed that UDCA and TUDCA rescued the increase in the ratio of Firmicutes to Bacteroides in the gut of a mouse model of colitis. 175 Given that altered firmicutes to bacteroides is observed in AD and PD, 52 , 176 UDCA may reduce NDD‐associated gut microbiome alterations which may precede disease onset. 177 UDCA was also reported to increase the colonization rate of Akkermansia muciniphila, 178 a bacterial species that has been positively correlated with cognitive improvements and reduced neuroinflammation in the context of NDDs. 179 , 180 These studies highlight the potential of microbiome‐targeted combination therapies as a novel strategy for PD treatment, though further clinical validation is needed to confirm these effects in humans. In fact, dietary‐based strategies such as the ketogenic and Mediterranean diets to increase the abundance of UDCA‐producing bacterial taxa may prove beneficial in ameliorating NDD‐related phenotypes. 181 , 182 The relationship between UDCA and the gut microbiome, however, may be complicated as dietary fibre such as pectin and inulin—which have otherwise been shown to result in various benefits—were previously shown to lower bile acid concentrations including UDCA. 183 Additionally, Ruminococcus gnavus, a bacterial species shown to produce UDCA was also shown to be elevated in irritable bowel syndrome 184 and fast‐food consumption in the context of Crohn's disease and ulcerative colitis. 185 The abundance of bile acid‐producing bacterial taxa in pathological conditions further highlights the fine balance that needs to be maintained when trying to leverage the gut‐brain axis to alleviate detrimental brain phenotypes. Although leveraging strategies that may increase the abundance of UDCA‐yielding bacterial taxa 186 may seem intuitive, more research should be conducted to investigate the effects of gut microbiota‐mediated UDCA production given that reports have shown beneficial effects of such processes in combating peripheral inflammation. 119 Personalised medicine approaches Inter‐individual variability in drug response is one of the challenges in treating PD and AD effectively. Factors such as genetic variations, age‐related physiological changes, gender, polypharmacy interactions, and lifestyle factors will all contribute to divergent therapeutic outcomes. 187 This emphasises the need for personalised medicine approaches that integrate genomic, lifestyle, and environmental data to optimise treatment strategies. 188 Tailoring UDCA treatment based on genetic profiles such as LRRK2 or GBA1 mutations in PD and APOE variants in AD, disease subtypes, and metabolic characteristics could enhance therapeutic outcomes. 189 , 190 Emerging strategies could leverage genetic networks identified through GWAS and transcriptomic data to identify novel therapeutic targets and repurpose existing drugs like UDCA for specific patient subgroups. 191 As research advances, the integration of these multidimensional data will be crucial for developing precision dosing regimens to maximise UDCA's therapeutic effects in both PD and AD. Alternative delivery systems One of the limitations in UDCA for treating PD and AD is its therapeutic potential is limited by modest BBB penetration, low bioavailability, and rapid systemic clearance. 140 , 192 The BBB acts as a highly selective, lipophilic barrier that restricts the entry of most hydrophilic compounds, 192 , 193 such as UDCA, which is hydrophilic in nature, 114 so it is not lipophilic enough to go through the BBB efficiently. Nevertheless, some studies have demonstrated that UDCA can enter the CNS in a dose‐dependent manner. For example, In vitro models have shown UDCA's ability to cross human brain microvascular endothelial cells over time 130 Parry et al. reported that UDCA is well absorbed after oral administration and crosses the BBB in a dose‐dependent manner. 131 As demonstrated in the UP study on PD, the brain requires high‐dose UDCA administration at 30 mg/kg/day to achieve therapeutic effects, 143 which is twice the dose used to treat PBC (13.5 mg/kg/day). 194 To overcome these challenges, novel delivery systems are being explored to enhance CNS targeting, prolong circulation, and minimise off‐target effects. Alternative routes of administration, such as nasal administration of geraniol‐UDCA (GER‐UDCA) prodrug encapsulated in solid lipid nanoparticles has enabled direct nose‐to‐brain delivery, that achieves therapeutic concentrations in cerebrospinal fluid (11–4.65 μg/mL) without systemic exposure or nasal mucosa damage, while synergising UDCA's mitochondrial protection with geraniol's anti‐inflammatory effects. 195 Additionally, nanovesicle‐based systems, particularly macrophage‐derived nanoparticles loaded with UDCA, have shown the ability to cross the BBB and localise in the brain as early as 0.5 h after administration in PD models, and modifying these nanovesicles with triphenylphosphonium enhanced the delivery of UDCA to injured mitochondria, leading to higher expression of tyrosine hydroxylase in striatal neurons, as compared to free UDCA. 140 These advanced delivery methods could transform UDCA into a more effective precision therapy for PD and patients with PD. Further clinical validation of these methods can be done to translate these technological advances into practical treatments. CONCLUSIONS In conclusion, this review highlights the neuroprotective potential of UDCA in the management of NDDs, particularly PD and AD, as it can target multiple shared pathogenic mechanisms of the disorders, such as mitochondrial dysfunction, oxidative stress, apoptosis, neuroinflammation and impaired autophagy. While UDCA is not a first‐line treatment, it can be used as an alternative therapeutic candidate as a mitochondrial stabiliser with the potential to delay disease progression. Both preclinical and clinical studies have supported the promising neuroprotective effects of UDCA in NDDs, but current clinical evidence remains limited, and findings from model systems may not fully translate to humans. While UDCA acts as a hepatoprotective agent, its repurposing for chronic neurodegenerative conditions requires careful consideration of potential long‐term risks, including hepatobiliary side effects at higher dosages required for CNS penetration. Furthermore, optimal dosing regimens remain to be established, and inter‐individual variability in patient response, likely influenced by genetic factors and disease heterogeneity, must be addressed. Therefore, larger clinical trials in diverse populations are essential to validate UDCA's efficacy, determine optimal dosing regimens, and assess its long‐term safety in PD and AD management. AUTHOR CONTRIBUTIONS Ashley En Yi Chong: Conceptualization (lead); writing—original draft (lead); writing—review and editing (supporting). Andrew Octavian Sasmita: Supervision (supporting); writing—review and editing (lead). Rhun Yian Koh: Conceptualization (supporting); supervision (supporting); writing—review and editing (supporting). Anna Pick Kiong Ling: Conceptualization (lead); supervision (lead); writing—review and editing (supporting). CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS STATEMENT The authors have nothing to report. ACKNOWLEDGMENTS A.O.S. is supported by the Walter Benjamin postdoctoral fellowship from the Deutsche Forschungsgemeinschaft (DFG grant 555827182). Chong AEY, Sasmita AO, Koh RY, Ling APK. Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease. Neuroprotection. 2026;4:111‐130. 10.1002/nep3.70039 Managing Editor: Ningning Wang Contributor Information Andrew Octavian Sasmita, Email: asasmita@ucc.ie. Anna Pick Kiong Ling, Email: anna_ling@imu.edu.my. DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data was created in this study. REFERENCES Associated Data Data Availability Statement Data sharing is not applicable to this article as no new data was created in this study.